Use of Novel Hormonal Agents and Systemic Therapy in Advanced Prostate Cancer Webcast (2018): Session I: Guidelines and Treatment Strategies
Urologists continue to indicate one of the greatest educational needs in integrating systemic agents into the management of advanced prostate cancer. With numerous new treatments now available to urologists to manage advanced disease, sequencing and managing the side effects of each treatment have become increasingly important. In addition, studies are demonstrating that earlier treatment with these systemic agents has improved efficacy. Urologists play a central role in the management of advanced, metastatic and castrate resistant prostate cancer and as their role continues to increase, knowledge of the various side effects of the numerous treatments that are available is paramount.
This course will provide essential information on the role of systemic therapy in the treatment of advanced prostate cancer, focusing upon a thorough review of the AUA CRPC Guidelines, followed by management of castrate sensitive prostate cancer with systemic agents, sequencing of agents, managing side effects of treatments, management of comorbid conditions, and identifying potential interactions between agents. Additionally, the course will include a section on pain management and training on counseling/support of patients in end-of-life issues.
This educational series is supported by independent educational grants from:
- Astellas and Pfizer Inc.
- Genomic Health
- Sanofi Genzyme
- Medical Oncologists
- Radiation Oncologists
- Advanced Practice Providers
- Nursing Staff
At the conclusion of this activity, participants will be able to:
- Apply the AUA CRPC Guidelines for optimization of the AUA algorithm for patient clinical benefit.
- Implement systemic treatment strategies for men with biochemical relapse but non metastatic castration resistant prostate cancer.
- Analyze the role of systemic agents in androgen sensitive metastatic prostate cancer.
- Examine the side effect profiles and potential interactions of various therapeutic strategies for CRPC.
- Oversee comorbid conditions and describe their management in the context of CRPC treatment.
- Discuss the potential roles of biomarkers in the use of systemic therapy for prostate cancer.
- Manage both the acute and chronic pain that is inherent in the care of CRPC patients.
- Communicate the pertinent end-of-life issues that surround CRPC patients and their families.
Session I: Guidelines and Treatment Strategies
Overview of AUA CRPC Guidelines: Daniel W. Lin, MD
Treatment Sequencing and Combinatorial Strategies in CRPC: Richard J. Lee, MD, PhD
Session II: Side Effect Management and Toxicities of Therapy
Comorbidities and Side Effect Profiles – Considerations for Various CRPC Therapeutic Strategies: Atish Choudhury, MD
Management of M0 CRPC and Future Directions in Systemic Therapy: Atish Choudhury, MD
Management of Castrate Sensitive Metastatic Disease and Bone Health: Richard J. Lee, MD, PhD
Session III: Enhancing Care through Patient Selection and Clinic Optimization
Practical Guide to an Advanced Prostate Cancer Clinic: Lawrence I. Karsh, MD, FACS
Biomarkers for Advanced Prostate Cancer: Ready for Prime Time?: Daniel W. Lin, MD
Session IV: Quality and End-of Life Issues in CRPC
Acute and Chronic Pain Management in CRPC: Russell Szmulewitz, MD
End-of-life Issues in CRPC Patients and Their Families: Russell Szmulewitz, MD
Session V: Revisiting the Index Patients with a New Perspective
Case Study 1 – Metastatic CRPC
Case Study 2 – M0 CRPC
Case Study 3 – M1 Asymptomatic CRPC/Pre-docetaxel
Case Study 4 – M1 Symptomatic Post-docetaxel
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 2.00 hours
Release Date: November, 2018
Expiration Date: November, 2019
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation